| Document |
Document Title |
|
WO/2024/044730A1 |
The invention provides pyrazolylsulfonamide compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), and their use in the treatment of a disease or condi...
|
|
WO/2024/042185A1 |
Disclosed herein are compounds of the formula (I), or pharmaceutically acceptable salts thereof: wherein R1 and R2 independently represent a hydrogen atom or a deuterium atom; R3' and R3" independently represent a hydrogen atom, a methyl...
|
|
WO/2024/040668A1 |
A Palbociclib saccharinate crystal form and a preparation method therefor. A prepared Palbociclib saccharinate crystal form α has excellent physical and chemical stability, high solubility, and good dissolution, fluidity and bioavailabi...
|
|
WO/2024/042007A1 |
The invention relates to substituted bicycles of the general formula I, and the use of the compounds of the present invention for the treatment and/or prevention of hyperproliferative diseases and disorders in mammals, especially humans,...
|
|
WO/2024/042104A1 |
The application relates to the use of an antibody molecule that binds to MSLN and CD137 and a PD-1/PD-L1 inhibitor in the treatment of cancer in a patient.
|
|
WO/2024/044647A1 |
Provided herein are polypeptides, compositions, and methods for treating a cancer in an individual using a polypeptide comprising a thrombopoietin domain and a Flt3 ligand domain. Also provided herein are nucleic acids encoding such poly...
|
|
WO/2024/044554A1 |
Described herein are immunoconjugates comprising an: a) antigen binding region; b) an immunoglobulin heavy chain constant region; and c) a radioisotope chelating agent; wherein the molecular weight of said immunoconjugate is between 60 a...
|
|
WO/2024/042494A1 |
The inventive compounds are small molecule therapeutics that are potent inhibitors of USP7 activity. The invention also provides pharmaceutical compositions comprising the compounds, and methods for using the compounds for treating or pr...
|
|
WO/2024/044774A2 |
Provided herein is a neoadjuvant therapy and/or adjuvant therapy for the treatment of uveal melanoma, inter alia, ocular tumors in uveal melanoma to reduce the incidence of metastasis and/or enucleation and/or preserving eye function.
|
|
WO/2024/040453A1 |
The present invention belongs to the field of medicines and relates to a mutated influenza virus, a pharmaceutical composition, and use. Specifically, the present invention relates to a replication-defective influenza virus, a pharmaceut...
|
|
WO/2024/041532A1 |
The present disclosure relates to a complex comprising a tetravalent platinum moiety and an oligopeptide as an axial ligand chemically linked to the platinum.
|
|
WO/2024/043643A1 |
The present invention relates to an IL2 variant and a protein complex comprising same, a production method therefor, and a use thereof, the protein complex selectively increasing effector T cell activity, thereby being capable of reducin...
|
|
WO/2024/042497A1 |
The present disclosure provides SEZ6 antibody drug conjugates (ADCs) comprising topoisomerase I inhibitors, including compositions and methods of using such ADCs.
|
|
WO/2024/041621A1 |
The invention provides K-Ras mutant protein inhibitors of formula (â… ), a composition containing the same and the use thereof.
|
|
WO/2024/041605A1 |
The present invention relates to multiple crystalline forms of a pharmaceutically acceptable salt of a compound N-cyclopropyl-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyri
din-3-yl)methyl)piperazin-1-yl)picolinamide, a preparation metho...
|
|
WO/2023/045266A9 |
The use of FGFR and a related signaling pathway inhibitor thereof in the preparation of a drug for treating an FGFR2 mutant tumor. An FGF/FGFR2 signal drives formation of triple negative breast cancer and promotes an epithelial-to-mesenc...
|
|
WO/2024/042157A1 |
Disclosed herein is a compound, or a pharmaceutically acceptable salt thereof, in particular hydrochloride salt thereof, characterized in that said compound is selected from the following compounds: - 4-(4-((1-(3-fluoropropyl)azetidin-3-...
|
|
WO/2024/044545A1 |
Described herein are approved products and methods of using approved products for treating relapsed or refractory multiple myeloma in a patient. Also described herein are methods of selling or offering for sale an approved product.
|
|
WO/2024/041315A1 |
The present disclosure provides anti-LILRB2 antibodies or antigen-binding fragments thereof, pharmaceutical compositions comprising the same and the uses thereof.
|
|
WO/2024/043836A1 |
The present invention relates to an engineered disulphide-linked ferritin assembly comprising at least one modified ferritin subunit, wherein the at least one modified ferritin subunit comprises the amino acid sequence set forth in SEQ I...
|
|
WO/2024/041651A1 |
The present disclosure provides a method of cancer treatment or enhancing an immune response, the method comprising administering to a patient an effective amount of an anti-PD1 antibody or antigen-binding fragment thereof in combination...
|
|
WO/2024/041573A1 |
This application discloses compounds of formula (I), which can be inhibitors of KRAS G12D or other KRAS mutants, and their uses.
|
|
WO/2024/041579A1 |
Disclosed is a multi-specific antibody targeting CD40 and PD-L1, as well as its use in the treatment of diseases such as tumors.
|
|
WO/2024/044675A1 |
The present disclosure provides a method of cancer treatment or enhancing an immune response, the method comprising administering to a patient 200 mg once every 3 weeks of an anti-PDl antibody or antigen-binding fragment thereof in combi...
|
|
WO/2024/044788A2 |
A method for treating a disease or disorder includes administering to a subject an effective amount of an agent that promotes the polarization of macrophages. The macrophages selectively repolarize their phenotype in the microenvironment...
|
|
WO/2024/041606A1 |
The present invention provides a compound represented by formula (I) for use as a KRAS inhibitor, a pharmaceutical composition comprising the compound, a method for preparing the compound, and use of the compound in treating a cancer.
|
|
WO/2024/042187A1 |
Disclosed herein are compounds of the formula (I) or a pharmaceutically acceptable salt thereof (I) Wherein R1 and R2 independently represent a hydrogen atom or a deuterium atom; R3' and R3" independently represent a hydrogen atom, a met...
|
|
WO/2024/041541A1 |
The present disclosure relates to a novel thiol reductant having the formula (I), the preparation and the use in the preparation of an antibody with thiol group site-specific modifications with improved homogeneity.
|
|
WO/2024/044304A1 |
A CRISPR-Cas9 system for treating a disease, disorder, or condition associated with one or more somatic mutations in a subject in need of treatment thereof is disclosed. The system comprises a sgRNA-guided Cas9, wherein the sgRNA targets...
|
|
WO/2024/041526A1 |
Provided is a polypeptide vector for delivering a nucleic acid medicament. An amino acid composition of the polypeptide vector is as represented by SEQ ID NO. 3. Also provided are use of the polypeptide vector, a corresponding nucleic ac...
|
|
WO/2024/041574A1 |
Provided herein are uses of conjugates of anti-CLDN18.2 antibodies or antigen-binding fragments thereof with radionuclides in imaging, patient screening, treatment process monitoring and efficacy evaluation.
|
|
WO/2024/043741A1 |
The present invention relates to a novel compound for the inhibition of autotaxin, a stereoisomer thereof, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing s...
|
|
WO/2024/044570A1 |
Disclosed are compounds of Formula (I): or a pharmaceutically acceptable salt, a tautomer, a stereoisomer, or a deuterated analog thereof, wherein R1, R2, A, E1, E2, and G are as described in any of the embodiments described in this disc...
|
|
WO/2024/042105A1 |
The application relates to the use of an antibody molecule that binds to MSLN and CD137 and a chemotherapeutic in the treatment of cancer in a patient.
|
|
WO/2024/042152A1 |
Disclosed herein are compounds of the formula (I), or pharmaceutically acceptable salts thereof, wherein R1 and R2 independently represent a hydrogen atom or a deuterium atom; R3' and R3" independently represent a hydrogen atom, a methyl...
|
|
WO/2024/044757A1 |
The present disclosure provides compounds and compositions that are useful as MYC protein modulators and methods of using the same for treating MYC-mediated diseases or disorders.
|
|
WO/2024/041503A1 |
The present invention discloses compounds of formula (I) which can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. Also provided are processes for ...
|
|
WO/2024/037422A1 |
The present disclosure relates to crystalline forms of (E) -N- ( (1R, 2R) -1- (3-chloro-4-cyclopropoxyphenyl) -1-hydroxy-3- (pyrrolidin-1-yl) propan-2-yl) -2- (6-chloronaphthalen-2-yl) -2- (hydroxyimino) acetamide, the method of preparin...
|
|
WO/2024/040194A1 |
Disclosed are methods of conditioning subjects who receive, are receiving, or have received an agent for in vivo reprogramming of immune cells in order to improve the efficiency of the in vivo reprogramming and/or the overall therapeutic...
|
|
WO/2024/038128A1 |
The present invention relates to compounds of Formulas I to V and la to Va, their use as activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) and to these compounds for use in a method for the treatment...
|
|
WO/2024/038462A1 |
rovided are compositions-of-matter comprising non-pathogenic bacteria capable of homing to a tumor, said bacteria comprising a heterologous polynucleotide comprising a nucleic acid sequence encoding a Pro Domain (TPD) polypeptide of TNFÎ...
|
|
WO/2024/039925A1 |
What is disclosed herein is a method for treating a cancer or tumor in an individual, comprising administering to the individual an ROR1 antagonist and a Bruton's tyrosine kinase inhibitor (BTKi), wherein the tumor or cancer comprises a ...
|
|
WO/2024/040241A1 |
The present disclosure relates to pharmaceutical formulations, for the treatment of cancer, and processes for the preparation of such compositions. The invention also relates to methods of administering such pharmaceutical formulations t...
|
|
WO/2024/037558A1 |
The present invention relates to novel forms of Compound I, preparation thereof, pharmaceutical composition containing the same and use thereof, wherein, the compound is (S) -5- ( (1- (3- (5-methyl-3- (trifluoromethyl) -8, 9-dihydropyrid...
|
|
WO/2024/037531A1 |
Provided are an anti-PSMA single-chain antibody, a chimeric antigen receptor associated therewith and use thereof. An amino acid sequence of a heavy chain of the anti-PSMA single-chain antibody includes a sequence shown in SEQ ID NO: 1, ...
|
|
WO/2024/040151A1 |
Dosing regimens and methods for administering combination therapies combining SIRPαFc fusion proteins and anti-CD38 antibodies are provided, such as the SIRPαFc fusion protein TTI-622 and the anti-CD38 antibody isatuximab. The dosing r...
|
|
WO/2024/037527A1 |
Provided herein are heteroaromatic compounds which target BTK proteins for ubiquitination and proteasomal degradation. Also provided herein are methods for using said compounds for the treatment of diseases.
|
|
WO/2024/040024A1 |
The ICAM-1/CD54 protein has been found to be a suppressor of antibody-mediated humoral immunity facilitated through its direct binding to the CH3 domain within IgG1 heavy chains. Its binding suppresses antibody immune-effector activity b...
|
|
WO/2024/036372A1 |
The present invention relates to formulations of radiolabelled compounds that are of use in radiotherapy and diagnostic imaging. Specifically, the present invention relates to aqueous formulations of 67 Cu radiolabelled compounds of Form...
|
|
WO/2024/038378A1 |
The present invention is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, which are useful as CBL-b inhibitors, processes for their preparation, pharmaceutical compositions comprising the compounds, and...
|
